Bone Loss, Chronic Periodontitis, Intrabony Periodontal Defect
Conditions
Keywords
intrabony periodontal defect, regeneration, platelet rich fibrin, bioactive glass
Brief summary
The aim of this study is to evaluate and compare the regenerative potential of Advanced Platelet Rich Fibrin (A-PRF) and Bioactive Glass (Perioglas®) bone graft in the treatment of intrabony defects in chronic periodontitis patients.
Detailed description
45 sites with vertical intrabony alveolar defects will be selected. These defect sites will be allocated randomly into 3 groups as Group I, Group II and Group III. * Group I will be treated with open flap debridement and filled with A-PRF * Group II will be treated with open flap debridement and filled with Bioactive glass (Perioglas®) * Group III will be treated with open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF.
Interventions
PROCEDUREopen flap debridement and filled with A-PRF ( Advanced platelet rich fibrin)
After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
PROCEDUREopen flap debridement and filled with Bioactive glass (Perioglas®)
After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
DRUGopen flap debridement and filled Bioactive glass (Perioglas®) and A-PRF
After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
Sponsors
Maharishi Markendeswar University (Deemed to be University)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
patient and statistician will be masked about the treatment regimen
Intervention model description
45 sites with vertical intrabony alveolar defects will be selected. These defect sites will be allocated randomly into 3 groups as Group I, Group II and Group III. * Group I will be treated with open flap debridement and filled with A-PRF * Group II will be treated with open flap debridement and filled with Bioactive glass (Perioglas®) * Group III will be treated with open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF.
Eligibility
Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Age: 25 to 55 years. * Gender: Both males and females will be included in the study. * Co-operative and motivated patients committed to oral hygiene. * Patients exhibiting intrabony defects.
Exclusion criteria
* Patients with contraindication to periodontal surgery & local anesthesia. * Any systemic disease affecting the bone density and outcome of periodontal therapy. * Smokers, alcoholics, and patients with other adverse habits. * Pregnant, nursing and menopausal women. * Any known allergy/ hypersensitivity to any product used in this study. * Patients on long-term systemic therapy (antibiotics, anti-inflammatory bisphosphonates, hormonal replacement therapy and any other), taking any drug known to have periodontal implications that may interfere with wound healing. * Patients taking any anti-platelet and anticoagulant medication. * Patients who have undergone periodontal treatment within a period of past 1 year.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| probing depth | baseline, 3 months, 6 months | change in probing pocket depth |
| relative attachment level | baseline, 3 months, 6 months | change in attachment level |
| radiographic linear bone change | change from baseline to 6 months | radiographic linear bone change through radiographic grid |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plaque index site specific | baseline, 3 months, 6 months | Plaque index -Silness and Loe |
| Gingival index site specific | baseline, 3 months, 6 months | Gingival index- Loe and Silness |
Countries
India
Outcome results
None listed